The comprehensive metabolic panel market is expected to register a CAGR of 7.2% during the forecast period, 2021-2026. The market is majorly driven by the growing awareness among the population regarding early diagnosis and treatment of diseases and the increasing prevalence of chronic diseases. Also, advancements in point-of-care technologies and diagnostics are expected to boost the market growth over the coming years.
With the increase in COVID-19 patients, the testing has expanded across the globe, which has stimulated the rise in blood tests being performed, and health officials expect a significant increase in the number of COVID-19 patients. Therefore, as the prevalence of COVID-19 increases, the demand for blood testing also increases, which further boosts the overall market.
According to the International Diabetes Federation, in 2019, there were about 463 million adults found living with diabetes, which is expected to reach 700 million by 2045. The rising burden of diabetes and efforts of governments and other organizations to increase awareness among the population are anticipated to boost the market over the forecast period.
According to the Regents of the University of California in 2018, there are nearly 750,000 patients per year in the United States alone, and the disease disproportionately affects the nation’s minority and low-income patients. The estimates have also reported that there are around 2 million people worldwide suffering from end-stage renal disease (ESRD), and the number of patients diagnosed with the disease continues to increase at a rate of 5-7% per year. Countries such as Taiwan, Japan, Mexico, the United States, and Belgium currently have the highest prevalence of ESRD. Therefore, the increase in the prevalence of chronic diseases such as kidney diseases, diabetes, and liver diseases and emphasis of people on early diagnosis of these diseases are the factors responsible for the growth of the comprehensive metabolic panel (CMP) market.
The rise in demand for point-of-care testing for early detection and faster results by these tests are some other factors responsible for the growth of the market.
Key Market Trends
The Diabetes Segment is Projected to Grow at a Healthy Rate During the Forecast Period
Diabetes is one of the fastest-growing diseases that is widening the patient pool for point-of-care (PoC) CMP testing. The increasing prevalence of diabetes and cardiovascular and other target diseases is anticipated to boost the demand for CMP testing over the forecast period.
According to the International Diabetes Federation in 2019, over 463 million adults (20-79 years) were living with diabetes in 2019, and by 2045, this may rise to 700 million. More than 20 million live births, i.e., every 1 in 6 live births, is affected by diabetes during pregnancy. From these, approximately 10-15% of the population have Type 1 diabetes. The rise in prevalence of chronic diseases such as kidney diseases, diabetes, and liver diseases and emphasis of people on early diagnosis of these diseases are some of the factors responsible for the growth of the comprehensive metabolic panel (CMP) testing market.
The increase in demand for immediate diagnosis and the advent of new technologies transforming the point-of-care testing devices are projected to bolster the market over the forecast period. Moreover, the introduction and implementation of data-driven solutions in diagnostics for better evaluation of health conditions are driving the market growth furthermore.
The kidney diseases segment also has a notable share. The share is attributed to the growing prevalence of kidney diseases and increasing emphasis on early diagnosis among people. Owing to factors such as sedentary lifestyles, changing food habits, and increasing diabetic patients around the world, the segment is expected to grow at a significant rate over the period.
North America is Anticipated to Grow at a Significant Growth Rate During the Forecast Period
North America is projected to grow over the period due to the rising growth of the well-established healthcare infrastructure, the presence of major players, and the presence of a large patient population.
With the increase in COVID-19, there is a wide range of testing that has been performed on blood, and this increase in testing has stimulated the overall demand for a comprehensive metabolic panel market in the North American region.
Chronic kidney disease (CKD) has become a public health problem in the United States. According to the CDC data 2019, chronic kidney diseases (CKD) are found to be in 15% of US adults that is around 37 million people suffering from CKD. CKD is more common in people aged 65 years or older (38%) than in people aged 45-64 years (13%) or 18-44 years (7%). CKD is more common in women (15%) compared to men (12%). The rise in prevalence of chronic diseases such as kidney diseases, diabetes, and liver diseases are some of the factors responsible for the growth of the comprehensive metabolic panel (CMP) testing market.
Diabetes is found widening the patient pool for point-of-care (PoC) CMP testing. Diabetes and high blood pressure are found to be the major causes of CKD in adults. The other risk factors of diabetes include heart disease, obesity, a family history of CKD, past damage to the kidneys, and older age. Furthermore, there are favorable reimbursement policies and government support that are anticipated to aid the market growth in the region.
The comprehensive metabolic panel market is moderately competitive having local and international players in the market. Companies are focusing on collaborations and expanding into new geographies to strengthen their market shares. The key players operating in this market include Quest Diagnostics, Laboratory Corporation of America Holdings, ARUP Laboratories, Synlab Hrvatska, and UNIPATH, among others. These major players are increasingly focusing on strategic initiatives, such as product launches and developments, mergers and acquisitions, licensing partnerships, and co-development deals, making this market highly competitive.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Growing Awareness Regarding Early Diagnosis and Treatment of Diseases
4.2.2 Increasing Prevalence of Chronic Diseases
4.3 Market Restraints
4.3.1 Lack of Skilled Professionals
4.3.2 Stringent Regulatory Policies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.2 Kidney Tests
5.1.4 Liver Function Tests
5.1.6 Other Test Types
5.2 By Disease
5.2.1 Kidney Diseases
5.2.3 Liver Diseases
5.2.4 Other Diseases
5.3 By End User
5.3.1 Point-of-care Centers
5.4.1 North America
22.214.171.124 United States (By Test Type, Disease, and End User)
126.96.36.199 Canada (By Test Type, Disease, and End User)
188.8.131.52 Mexico (By Test Type, Disease, and End User)
184.108.40.206 Germany (By Test Type, Disease, and End User)
220.127.116.11 United Kingdom (By Test Type, Disease, and End User)
18.104.22.168 France (By Test Type, Disease, and End User)
22.214.171.124 Italy (By Test Type, Disease, and End User)
126.96.36.199 Spain (By Test Type, Disease, and End User)
188.8.131.52 Rest of Europe (By Test Type, Disease, and End User)
184.108.40.206 China (By Test Type, Disease, and End User)
220.127.116.11 Japan (By Test Type, Disease, and End User)
18.104.22.168 India (By Test Type, Disease, and End User)
22.214.171.124 Australia (By Test Type, Disease, and End User)
126.96.36.199 South Korea (By Test Type, Disease, and End User)
188.8.131.52 Rest of Asia-Pacific (By Test Type, Disease, and End User)
5.4.4 Middle-East and Africa
184.108.40.206 GCC (By Test Type, Disease, and End User)
220.127.116.11 South Africa (By Test Type, Disease, and End User)
18.104.22.168 Rest of Middle-East and Africa (By Test Type, Disease, and End User)
5.4.5 South America
22.214.171.124 Brazil (By Test Type, Disease, and End User)
126.96.36.199 Argentina (By Test Type, Disease, and End User)
188.8.131.52 Rest of South America (By Test Type, Disease, and End User)
6.1.1 Quest Diagnostics
6.1.2 Laboratory Corporation of America Holdings
6.1.3 Sonic Healthcare Limited
6.1.4 SYNLAB International GmbH
6.1.5 Charles River Laboratories Inc.
6.1.6 ARUP Laboratories
6.1.7 NeoGenomics Laboratories Inc.
6.1.8 Genoptix Inc.
6.1.9 CENTOGENE AG
6.1.11 Abbott Laboratories
6.1.12 Abaxis Inc. (Zoetis)
6.1.13 TCG Corp.
6.1.14 Scion Lab Services LLC
A selection of companies mentioned in this report includes:
- Quest Diagnostics
- Laboratory Corporation of America Holdings
- Sonic Healthcare Limited
- SYNLAB International GmbH
- Charles River Laboratories Inc.
- ARUP Laboratories
- NeoGenomics Laboratories Inc.
- Genoptix Inc.
- CENTOGENE AG
- Abbott Laboratories
- Abaxis Inc. (Zoetis)
- TCG Corp.
- Scion Lab Services LLC